Fish Oil

Fish oil is the most-widely-supplemented source of marine omega-3 fatty acids (EPA and DHA) and has been studied across cardiovascular disease prevention, triglyceride reduction, glycemic control in type 2 diabetes, joint and arthritis outcomes, dry eye disease, and many other applications. Most clinical trials labeled "omega-3" or "EPA/DHA supplementation" use a fish oil product as the intervention, which means the fish oil literature heavily overlaps with the broader marine-omega-3 evidence base. Fish oil products vary widely in concentration, EPA-to-DHA ratio, formulation (ethyl ester vs. triglyceride forms), and oxidation status, all of which complicate direct comparison between products.

The outcome dimensions covered most heavily are cardiovascular disease prevention (including the large updated meta-analyses covering more than 100,000 participants across many trials), triglyceride reduction (one of the most-studied biochemical outcomes across the fish oil literature), glycemic control in type 2 diabetes (where the literature spans decades of accumulated trials), joint and arthritis outcomes, pregnancy outcomes (typically using fish oil as the omega-3 source), and bleeding-risk safety (specifically studied because of a long-standing theoretical concern from platelet-function research).

Demographically, the literature is unusually broad: cardiovascular trials enroll wide adult age ranges with varied baseline risk; the type 2 diabetes literature has decades of accumulated trials; pregnancy literature is well-developed. Concentration matters substantially - standard fish oil capsules typically contain ~30% EPA+DHA, while concentrated formulations contain 60-90%. Form (triglyceride vs. ethyl ester) affects absorption: triglyceride-form fish oil is somewhat better-absorbed, particularly when taken without a fatty meal, though both forms perform adequately in trials.

Fish oil is generally well-tolerated. The most-common adverse effects are gastrointestinal: fishy aftertaste and burps, nausea, and loose stools, which improve with enteric-coated capsules, refrigeration, or splitting the dose. Cod liver oil products also supply vitamins A and D, which can be harmful in excessive amounts. Bleeding risk has been a long-standing theoretical concern because fish oil affects platelet aggregation; rigorous systematic reviews have not found a clinically meaningful increase in bleeding risk at typical supplemental doses, though data in patients on anticoagulants are limited and prescription labels advise periodic monitoring. The FDA concluded in 2019 that supplements providing no more than 5 g/day combined EPA+DHA are safe when used as labeled. Product quality (chiefly oxidation status) varies between manufacturers, and methylmercury is removed during purification and has not been found in omega-3 supplements; reputable brands use molecular distillation and publish third-party testing results. Large trials using 4 g/day for several years have reported a slightly increased risk of atrial fibrillation in people with or at high risk of cardiovascular disease. Drug interactions include theoretical additivity with anticoagulants (clinically less concerning than long-believed) and antihypertensives.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.